Comparison of deep and nondeep hypothermia in thoracic and thoracoabdominal aortic surgery: A systematic review and meta-analysis.

J Vasc SurgJun 24, 2026 (epub)
Clinical ResearchCardiothoracic Surgery

Milton Sérgio Bohatch Júnior, Leo Consoli, Elisabeth Amanda Gomes Soares et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the effects of deep hypothermic circulatory arrest (DHCA) versus non-DHCA techniques in thoracic and thoracoabdominal aortic aneurysm repair among 1041 patients. The study found that DHCA significantly reduced the risk of spinal cord injury (RR, 0.44; P = .012) but was associated with longer postoperative ventilation times (RR, 1.34; P = .003).

Key findings

  • DHCA was associated with a significantly lower risk of spinal cord injury (RR, 0.44; P = .012).
  • DHCA resulted in prolonged postoperative ventilation time (RR, 1.34; P = .003).
  • No significant differences were found in overall mortality or stroke rates between DHCA and non-DHCA groups.
  • Older patient cohorts showed longer recovery periods post-surgery.

Why it matters

Understanding the comparative risks and benefits of DHCA versus non-DHCA techniques is crucial for optimizing patient outcomes in thoracic and thoracoabdominal aortic surgeries, particularly regarding neuroprotection and recovery times.

Source

PubMed · PMID 42341998

Published in J Vasc Surg. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiothoracic Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.